Perivascular Adipose Tissue: the Sixth Man of the Cardiovascular System

Chak Kwong Cheng¹,² · Hamidah Abu Bakar³ · Maik Gollasch⁴,⁵ · Yu Huang¹,²

Published online: 31 August 2018
© Springer Science+Business Media, LLC, part of Springer Nature 2018

Abstract
Perivascular adipose tissue (PVAT) refers to the local aggregate of adipose tissue surrounding the vascular tree, exhibiting phenotypes from white to brown and beige adipocytes. Although PVAT has long been regarded as simply a structural unit providing mechanical support to vasculature, it is now gaining reputation as an integral endocrine/paracrine component, in addition to the well-established modulator endothelium, in regulating vascular tone. Since the discovery of anti-contractile effect of PVAT in 1991, the use of multiple rodent models of reduced amounts of PVAT has revealed its regulatory role in vascular remodeling and cardiovascular implications, including atherosclerosis. PVAT does not only release PVAT-derived relaxing factors (PVRFs) to activate multiple subsets of endothelial and vascular smooth muscle potassium channels and anti-inflammatory signals in the vasculature, but it does also provide an interface for neuron-adipocyte interactions in the vascular wall to regulate arterial vascular tone. In this review, we outline our current understanding towards PVAT and attempt to provide hints about future studies that can sharpen the therapeutic potential of PVAT against cardiovascular diseases and their complications.

Keywords Adipose tissue · Perivascular relaxing factor · PVRF · KCNQ-type Kv7 channels · Beige adipocytes · Exercise · Perivascular nerves

Key points
• A functionally unique and specialized adipose tissue aggregate, termed perivascular adipose tissue (PVAT), encapsulates most of the blood vessels within the vascular tree.
• PVAT demonstrates phenotypic and functional heterogeneity, sandwiched between brown adipose tissue and white adipose tissue. PVAT microenvironment demonstrates heterogeneity, consisting of numerous cell types and molecules.
• Various animal models, either after specialized pretreatment protocol, with modified PVAT content or of human disease background are commonly used to verify the pathophysiological roles of PVAT in cardiovascular events.
• PVAT derives a wide spectrum of candidate molecules, including perivascular contracting/relaxing factors, adipocytokines including adipokines and inflammatory cytokines, and possibly miRNAs to regulate vascular tone, vascular inflammation, and vascular remodeling.
| Abbreviation | Definition |
|--------------|------------|
| ACE          | Angiotensin-converting enzyme |
| ADicerKO     | miRNA-processing enzyme Dicer |
| AdipoR       | Adiponectin receptor |
| ADRF         | Adipocyte-derived relaxing factor |
| Akt          | Protein kinase B |
| AMPK         | AMP-activated protein kinase |
| Ang1-7       | Angiotensin 1-7 |
| Ang II       | Angiotensin II |
| AT1          | Angiotensin II type 1 |
| AT1a         | Angiotensin II type 1a |
| AT2          | Angiotensin II type 2 |
| ATP          | Adenosine triphosphate |
| aP2          | Acid-binding protein |
| ApoE         | Apolipoprotein E |
| APN          | Aminopeptidase |
| AR           | Adrenoceptor |
| ASP          | Acylation stimulation protein |
| BAT          | Brown adipose tissue |
| BCA          | β-cyano-L-alanine |
| BK<sub>ca</sub> | Large conductance calcium-activated potassium |
| cAMP         | Cyclic adenosine monophosphate |
| CAST         | Calpastatin |
| cGMP         | Cyclic guanosine monophosphate |
| CGRP         | Calcitonin gene-related peptide |
| ChemR23      | Chemerin receptor 23 |
| CIDEA        | Cell death-inducing DNA fragmentation factor-α-like effector A |
| cir-miRNA    | Circulating miRNA |
| COX          | Cyclooxygenase |
| CPT<sub>1B</sub> | Carnitine palmitoyltransferase 1B |
| CSE/CTH      | Cystathionine gamma lyase |
| CVD          | Cardiovascular disease |
| CXC          | Cysteine-X-cysteine |
| CYP 450      | Cytochrome P450 |
| DRF          | Dorsal root ganglia |
| DIO          | Diet-induced obesity |
| EDHF         | Endothelium-dependent hyperpolarizing factor |
| EET          | Epoxidecysatrienoic acid |
| EFS          | Electric field stimulation |
| eNOS         | Endothelial nitric oxide synthase |
| ERK          | Extracellular signal-regulated kinase |
| F A T - ATTAC | Fat apoptosis through targeted activation of caspase 8 |
| FGF2         | Fibroblast growth factor 2 |
| FKBp         | FK506 binding protein |
| GC           | Guanylyl cyclase |
| H<sub>2</sub>O<sub>2</sub> | Hydrogen peroxide |
| HFD          | High-fat diet |
| HF/HS        | High-fat-high-sucrose |
| H<sub>2</sub>S | Hydrogen sulfide |
| HSV          | Herpes simplex virus-1 |
| IGF-1        | Insulin-like growth factor-1 |
| IKK          | I kappa B kinase |
| IL-1         | Interleukin 1 |
| IL-1β        | Interleukin 1β |
| IL-6         | Interleukin 6 |
| IL-6R        | IL-6 receptor |
| IL-8         | Interleukin 8 |
| IP           | Prostacyclin receptor |
| K<sub>ATP</sub> | ATP-sensitive potassium channels |
| KCNQ         | Potassium voltage-gated channel subfamily Q |
| K<sub>dr</sub> | Delayed-rectifier potassium channel |
| K<sub>v</sub> | Voltage-gated potassium channel |
| LDL          | Low-density lipoprotein |
| LDLR         | LDL receptor |
| LPS          | Lipopolysaccharide |
| MAPK         | Mitogen-activated protein kinase |
| MCP-1        | Monocyte chemotactic protein-1 |
| miRNA        | microRNA |
| BAT          | Brown adipose tissue |
| BCA          | β-cyano-L-alanine |
| BK<sub>ca</sub> | Large conductance calcium-activated potassium |
| cAMP         | Cyclic adenosine monophosphate |
| CAST         | Calpastatin |
| cGMP         | Cyclic guanosine monophosphate |
| CGRP         | Calcitonin gene-related peptide |
| ChemR23      | Chemerin receptor 23 |
| CIDEA        | Cell death-inducing DNA fragmentation factor-α-like effector A |
| cir-miRNA    | Circulating miRNA |
| COX          | Cyclooxygenase |
| CPT<sub>1B</sub> | Carnitine palmitoyltransferase 1B |
| CSE/CTH      | Cystathionine gamma lyase |
| CVD          | Cardiovascular disease |
| CXC          | Cysteine-X-cysteine |
| CYP 450      | Cytochrome P450 |
| DRF          | Dorsal root ganglia |
| DIO          | Diet-induced obesity |
| EDHF         | Endothelium-dependent hyperpolarizing factor |
| EET          | Epoxidecysatrienoic acid |
| EFS          | Electric field stimulation |
| eNOS         | Endothelial nitric oxide synthase |
| ERK          | Extracellular signal-regulated kinase |
| F A T - ATTAC | Fat apoptosis through targeted activation of caspase 8 |
| FGF2         | Fibroblast growth factor 2 |
| FKBp         | FK506 binding protein |
| GC           | Guanylyl cyclase |
| H<sub>2</sub>O<sub>2</sub> | Hydrogen peroxide |
| HFD          | High-fat diet |
| HF/HS        | High-fat-high-sucrose |
| H<sub>2</sub>S | Hydrogen sulfide |
| HSV          | Herpes simplex virus-1 |
PVAT Heterogeneity

Depending on the regions in the vascular bed where PVAT is located, PVAT displays phenotypic and functional heterogeneity [3, 8]. PVAT majorly exhibits several defining features of brown adipose tissue (BAT), including the presence of multiple lipid droplets, high mitochondrial content, and expression of thermogenic genes (like *Ucp-1*) [9]. However, certain PVAT (like mesenteric PVAT) has been characterized as white adipose tissue (WAT)-like, due to the presence of relatively large lipid droplets, low mitochondrial content, and the relatively low expression levels of uncoupling protein 1 (*UCP-1*) [10]. In contrast, certain PVAT (like coronary PVAT) is more beige adipose tissue-like since the expression levels of brown adipocyte-related genes, including cell death-inducing DNA fragmentation factor-α-like effector A (*CIDEA*), *UCP-1*, and carnitine palmitoyltransferase 1B (*CPT1B*), are apparently different from those of typical BAT in studies using fat deposits collected from 129SVE mice and human [11, 12]. Hence, with features that could hardly fit into the predefined fat tissue, it is reasonable to categorize PVAT as the fourth type of adipose tissue [9, 13].

PVAT Microenvironment

PVAT plays active paracrine/endocrine roles in regulating arterial vascular tone of enclosed blood vessels and its microenvironment consists of various cell types and molecules (Fig. 1). Above tunica adventitia, adipocytes within PVAT (either brown-like, white-like, or beige-like) are responsible for the production of many biologically active molecules, with possible autocrine and/or paracrine effects, modulating vascular function and cardiometabolic complications [13, 14]. In brief, these molecules can be categorized into putative vasoactivators, including both perivascular contraction factors (PVCFs) and perivascular relaxing factors (PVRFs) [15, 16], adipokines like adiponectin, leptin, and resistin, cytokines such as tumor necrosis factor-α (TNF-α) and interleukins, and certain gaseous molecules like nitric oxide (NO) and hydrogen sulfide (H₂S) [17, 18]. Through secretion of cytokines during the pathogenesis of atherosclerosis, PVAT was confirmed, in both rodents and human atherosclerotic aortae [19], to promote the recruitment and infiltration of immune cells, including macrophages and T cells, which in terms produce additional chemokines initiating a feed-forward loop for inflammatory response [19, 20]. Furthermore, resident multipotent stem cells within PVAT, named mesenchymal stem cells (MSCs), show multiple differentiation capacity towards adipocytes, endothelial cells, smooth muscle cells (SMCs) and osteoblasts for repair and replacement [21–23]. For instance, isolated human perivascular stem cells were able to undergo in vitro osteogenic differentiation and form bone in vivo after intramuscular implantation in male severe
combined immunodeficiency (SCID) mice [24]. PVAT also provides an interface for interactions between perivascular adipocytes and autonomic perivascular nerve [25]. In brief, perivascular adipocytes express different receptors, including adrenoceptors (ARs), receptors for neuropeptide Y (NPY), and purinoceptors, sensing neurotransmitters secreted by adjacent sympathetic nerve [25, 26]. Recently, studies also provide hints that PVAT might be a potential source of microRNAs (miRNAs) by releasing microvesicles or exosomes, which may either enter circulation or transfer into nearby adipocytes or macrophages for endocrine functions and inflammatory communications [27–29].

**Experimental Model**

In addition to its well-established roles in providing structural support to vasculature and in thermoregulation of intravascular temperature [30], PVAT plays significant roles in modulating the onset and progression of many CVDs, including atherosclerosis and hypertensive heart diseases [5, 31]. Various animal models, either after pretreatment protocol (Table 1), with modified PVAT content (Table 2), or of human disease background (Table 3), have been used to emphasize the importance of PVAT in cardiovascular events. In this session, we attempt to summarize the major animal models in the context of vascular tone regulation, atherosclerosis, vascular remodeling, angiogenesis, and hypertensive disorders.

**Pretreatment Protocol**

Animals and/or their tissues might undergo acute or chronic procedure prior to experiments on vascular reactivity assay. Since the first-time discovery of anti-contractile effect of PVAT against norepinephrine on isolated rat aorta by Soltis and Cassis in 1991 [32], abundant acute ex vivo experiments investigating the effect of PVAT on vascular function have been carried out, using isolated blood vessels from rat, mouse, swine, rabbit, and human [32–37]. Depending on the nature of the study, the interaction between PVAT and different regions of vascular bed, like aorta, mesenteric artery, and coronary artery, were investigated [33, 38]. For instance, mouse small mesenteric arteries, together with PVAT, were isolated and mounted on a wire myograph to study how adiponectin activates large conductance calcium-activated potassium (BK\textsubscript{ca}) channels or other pathways to induce anti-contractile responses ex vivo [39, 40].
In addition, chronic diet-induced obese animal model is generally used to provide pathophysiological mimetics to study the vasoregulatory roles of PVAT. Following the feeding of high-fat diet (HFD), normally lasting for 3 to 4 months, the mouse of diet-induced obesity (DIO) is sacrificed to evaluate the impact of PVAT on vascular function in the state of obesity [41, 42]. Using the C57BL/6J mouse model of DIO, Li and his group showed the role of endothelial nitric oxide synthase (eNOS) uncoupling in PVAT underlying obesity-related vascular dysfunction [43]. Recently, the significance of exercise is increasingly recognized, so research groups started to use chronic exercise animal model in their studies. After male Wistar rats were trained on a treadmill designated for small animals with individual lanes for about 8 weeks, the thoracic aortae with PVAT were isolated for vascular function assay [44, 45]. However, routine exercise results in broad effects in metabolic profile of trained animals that it may not be easy to draw a direct link between PVAT and the improved vascular function.

Transplantation is a common procedure in exploring the function of PVAT in atherogenesis and vascular remodeling. Normally, researchers might transplant PVAT from an artery to another or replace PVAT with viscera and subcutaneous adipose tissues [46, 47]. Takaoka et al. demonstrated that transplantation of subcutaneous fat from mice fed on normal chow could attenuate the enhanced neointima formation due to the removal of periadventitial adipose tissue in C57BL/6 mice fed with high-fat high-sucrose (HF/HS) diet [47]. Another study transplanted thoracic PVAT from donor mice to carotid arteries of recipient ApoE−/− mice to indicate the therapeutic potential of PVAT in promoting atherosclerotic plaque vulnerability [48].

**Modified PVAT Content**

In addition to the non-genomic experimental models, several transgenic rodent models with reduced or absent PVAT have been developed. The A-ZIP/F mouse is one of the currently

| Model | Phenotype | Cardiovascular event(s) | Limitation | Ref. |
|-------|-----------|------------------------|------------|------|
| A-ZIP/F | Complete ablation of WAT, reduced BAT and PVAT, fatty liver, diabetes, hyperlipidemia | • Not appropriate | • Too complex physiological phenotypes | [49, 50] |
| UCP-I-DT | Significant deletion of BAT, hyperphagia, diabetes, hypertriglyceridemia | • Unknown | • Incomplete deletion of BAT • Expression of 50% of Ucp1 mRNA | [52, 53] |
| Transgenic skinny | Complete deletion of adipose tissue, elevated glucose metabolism, small liver | • Not suitable for vascular function and hypertension studies • Overexpression of leptin | • Lack of reports on PVAT status | [54, 55] |
| FAT-ATTAC | Phenotypes similar to A-ZIP/F mouse, remarkable ablation of WAT and BAT, reduced systemic inflammation, glucose intolerance | • Unknown | • Lack of reports on PVAT status | [56] |
| SMPG KO | Presence of BAT and WAT, absence of PVAT, hypotension during resting period of circadian cycle | • Not suitable for blood pressure-related topics | • Problem of hypotension | [30, 57] |
available models, in the absence of WAT, and with dramatically reduced PVAT and BAT during lifetime, resulting in complex pathological phenotypes including hypertension and diabetes mellitus. In brief, the A-ZIP/F mouse expresses the dominant negative protein A-ZIP/F, under the control of an adipose-specific acid-binding protein (aP2) promoter. Although A-ZIP/F mouse exhibits altered vascular contractile activity, ex vivo co-incubation of its aorta with PVAT from wild-type (WT) mouse could not restore the impaired vascular function. Furthermore, Takemori et al. showed that the expression level of angiotensin II (Ang II) type 1 receptors is higher than that of Ang II type 2 receptors. These observations imply that the absence of PVAT may not be the cause of dysfunctional aortae, suggesting that A-ZIP/F mouse might not be suitable for understanding the interrelationship between PVAT and vascular tone regulation.

Several other mouse models with ablation of adipose tissue might be potentially suitable for PVAT study, including those of either inborn or inducible adipose deletion. In 1993, the UCP-I-DT transgenic mouse is considered one of the classical rodent models with complete ablation of BAT, with physiological phenotypes of hyperphagia, diabetes mellitus, and hypertriglyceridemia. However, it was later reported that UCP-I-DT model still retains a significant number of brown adipocytes, expressing approximately 50% of Ucp1 mRNA in the brown fat. Another potential transgenic model for PVAT study is named transgenic skinny, characterized with complete ablation of adipose tissue and increased glucose metabolism. However, this model is also accompanied by overexpression of leptin, meaning that it might complicate the study involving vascular tone and hypertension, in which leptin plays active regulatory roles.

In 2005, a relatively new mouse model named fat apoptosis through targeted activation of caspase 8 (FAT-ATTAC) was developed, through targeted utilizing of a caspase 8-FKBPv (Phe36Val mutant FK506 binding protein (FKBP)) fusion protein under the control of adipocyte-specific Fabp4 promoter. In short, through activation of caspase 8 to induce fat apoptosis, this mouse exhibits phenotypes close to A-ZIP/F mouse showing reduced WAT and BAT content, reduced systemic inflammation, and glucose intolerance. Despite the lowered fat content in these animals, there are still lacking reports on their PVAT status. In 2012, Chang and his colleagues developed a murine smooth muscle cell-selective PPARγ knockout (SMPG KO) model that is deficient in PPARγ in vascular smooth muscle cells (VSMCs), showing the presence of BAT and WAT depots but not PVAT. However, SMPG KO mice were hypotensive during the resting period of circadian cycle, which might not be suitable for examining the effect of PVAT on blood pressure regulation.

### Susceptibility to Human Diseases

Rodents with susceptibility to human diseases remain the species of choice to address the important roles of PVAT in the progression of atherosclerosis, hypertension, and vascular remodeling. Both apolipoprotein E-knockout (apoE<sup>−/−</sup>) mouse and low-density lipoprotein (LDL) receptor-deficient mouse (LDLr<sup>−/−</sup>) with significant higher LDL levels, are the standard models used in atherosclerosis research. These mice develop robust lesions to form atherosclerotic plaques on the Western diet or atherogenic diet. Hence, many studies examined the role of PVAT using apoE<sup>−/−</sup> mice. For example, transplantation of perivascular visceral adipose tissue from apoE<sup>−/−</sup> donors to the right common carotid artery, a site that typically does not develop spontaneous atherosclerosis, of apoE<sup>−/−</sup> recipients resulted in a more advanced atherosclerotic lesion with the evidence of atherothrombosis and endothelial dysfunction. Another study reported that periaortic adipose tissue (PAT) activated the renin-angiotensin system (RAS) to accelerate chronic kidney disease-associated atherogenesis. In addition, another study unraveled that PVAT contributes to aneurysm formation in an angiotensin II type Ia (AT<sub>1</sub>) receptor-dependent manner.

### Table 3 Rodent models with susceptibility to human diseases

| Model         | Phenotype                                      | Cardiovascular event(s)                                                                 | Limitation                                      | Ref.       |
|---------------|------------------------------------------------|-----------------------------------------------------------------------------------------|------------------------------------------------|------------|
| ApoE<sup>−/−</sup> mouse | Hypercholesterolemia, cardiac hypertrophy, poor vascular function, hypertension (aging) | • Atherosclerosis<br>• Anemia<br>• Arterial stiffness | Careful maintenance of animals<br>Specific diet needed | [58–61]   |
| LDLr<sup>−/−</sup> mouse   | Hypercholesterolemia, fatty streaks on the aorta, hypertension | • Atherosclerosis<br>• Vascular function<br>• Arterial stiffness | Careful maintenance of animals<br>Specific diet required<br>Lower total plasma cholesterol levels than ApoE<sup>−/−</sup> mouse | [62–64]   |
| SHR           | Hypertension, vascular hypertrophy, cardiac hypertrophy | • Hypertension<br>• Vascular function<br>• Arterial stiffness | Larger size, more space required | [65]       |
| NZO mice     | Hypertension, diabetes, obesity                 | • Hypertension<br>• Vascular function<br>• Arterial stiffness<br>• Diabetes<br>• PVAT malfunction | Careful maintenance<br>Breeding | [66–69]   |
Few studies used LDLr<sup>−/−</sup> mice, another well-recognized atherosclerotic model but with much lower total levels of plasma cholesterol than ApoE<sup>−/−</sup> mice under low fat chow diet [62]. However, the studies are not directly related to atherosclerosis that a recent report focused on how PAT-derived IL-6 contributes to arterial stiffness in LDLr<sup>−/−</sup> mice [63]. A most recent study shows the protective benefit of PAT in endothelial dysfunction and insulin-induced vasodilation of LDLr<sup>−/−</sup> mice [64]. Working on hypertensive rodent models provides useful clues about the contribution of PVAT to hypertension-related complications. Earlier studies examined the influence of hypertension on the anti-contractile effect of PVAT. Lu et al. suggested that changes in adipocyte composition of PVAT, but not its mass, might exacerbate vascular dysfunction in a spontaneously hypertensive rats (SHR) [65]. These studies were paralleled by studies using New Zealand obese (NZO) mice that exhibit PVAT malfunction on arterial tone regulation despite excess visceral adipose mass. The anti-contractile effects of PVAT were diminished in mesenteric arteries of NZO mice with age. Voltage-gated potassium channel subfamily Q (KCNQ) channel openers reduced arterial blood pressure in both models of hypertension independent of ganglionic blockade. Thus, our data suggest that KCNQ channels play a pivotal role in periaortiadal vasoregulation of peripheral skeletal muscle and visceral arteries, and KCNQ channel opening may be an effective mechanism to improve impaired PVAT vasoregulation and associated hypertension [17, 66]. We also found that BK<sub>Ca</sub> channels and/or K<sub>v</sub>1.5 channels in VSMCs are not the downstream mediators involved in the inhibitory effects of 4-pyridinylmethyl-9(10H)-anthraceneone (XE991) (a KCNQ channel blocker) on PVAT-dependent arterial relaxation [67]. KCNQ1 channels are apparently not involved in the control of arterial tone by α1-adrenoceptor agonists and PVAT [68]. Based on preclinical and clinical data, KCNQ channels (in particular KCNQ2-5 channels (K<sub>v</sub>7.2-5) in VSMCs can now be viewed as potential novel drug targets for treatment of resistant hypertension, particularly in comorbid conditions such as obesity and metabolic syndrome [69]. Taken together, the available data allowed us to propose that dysfunctional PVAT contributes to cardiovascular risks [11, 17].

**PVAT Candidates**

Accumulating evidence suggests that PVAT is a significant autocrine/endocrine/paracrine organ surrounding the vasculature. By secreting a wide spectrum of candidate molecules, including perivascular factors (like PVRFs and PVCFs), adipokines (like adipokines and angiotensins), inflammatory cytokines, and possibly miRNAs, PVAT plays a pivotal role in regulating vascular tone, vascular inflammation, and vascular remodeling through targeting different cell types in vasculature and even in the PVAT microenvironment including perivascular adipocyte itself (Fig. 2).

**Perivascular Factors**

Both PVAT and endothelium are now considered important paracrine tissues regulating the contractile state and homeostasis of underlying SMCs through the production of various substances [17]. PVAT adipocytes release bioactive signaling molecules, majorly categorized into PVRFs and PVCFs, to confer vasoregulatory effect [11]. Certain simple molecules (e.g., NO, H<sub>2</sub>S), reactive oxygen species (e.g., hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>)), and adipokines (e.g., adiponectin, angiotensin 1-7 (Ang1-7)) are notable PVRFs [6, 17], contributing to the anti-contractile effect of PVAT on vascular bed. In 1987, Palmer et al. remarkably discovered that endothelial cells produce NO, the critical endothelium-derived relaxing factor for proper vascular function [70]. Similar to endothelium, PVAT was shown to express eNOS to generate NO from l-arginine for the regulation of vascular tone [71], through NO-mediated upregulation of cyclic guanosine monophosphate (cGMP) levels and subsequent activation of protein kinase G [72, 73]. Importantly, knockout of protein kinase G accounted for the loss of anti-contractile effect of PVAT on the mouse mesenteric arteries [73].

Among PVRFs, adipocyte-derived relaxing factor (ADRF) is a transferable factor released by PVAT, through a Ca<sup>2+</sup>-dependent mechanism, to induce vasodilation of surrounding blood vessels [74]; nevertheless, the nature of ADRF has been long debated [17]. The volatile gaseous mediator H<sub>2</sub>S, which mediates the anti-contractile effect by opening KCNQ channels in VSMCs, was once suggested to be a primary candidate of ADRF [75]. In the cardiovascular system, H<sub>2</sub>S is extensively synthesized by cystathionine gamma lyase (CSE) encoded by CTH gene in both endothelial cells and perivascular adipocytes [76, 77]. Presence of CSE inhibitors DL-propargylglycine (PPG) and β-cyano-l-alanine (BCA) significantly attenuated the anti-contractile effect of PVAT in rat aortae ex vivo [78]. However, Gollasch et al. recently showed that CSE-derived H<sub>2</sub>S is unlikely to be the universal ADRF among different species since CSE inhibition by PPG and BCA only reduced the anti-contractile effect in rat but not in mouse aortae [79]. Lack of CSE also did not influence the anti-contractile effect of PVAT in mice [80]. Furthermore, H<sub>2</sub>O<sub>2</sub> is a reactive oxygen species (ROS) generated in both endothelium and PVAT either by spontaneous dismutation of superoxide (O<sub>2</sub><sup>−</sup>) or dismutation of O<sub>2</sub><sup>−</sup> by superoxide dismutases [72, 81]. Co-incubation of PVAT-intact rat aortae with catalase (a H<sub>2</sub>O<sub>2</sub> scavenger) results in an augmented vasorestriction, indicating the anti-contractile property of H<sub>2</sub>O<sub>2</sub> [71]. Unlike endothelium-derived H<sub>2</sub>O<sub>2</sub> which may induce either vasodilation or vasoconstriction depending on the concentration, vessel type, and species [82, 83], there is so far
only experimental evidence supporting the anti-contractile property of PVAT-derived H₂O₂ via the activation of soluble guanylyl cyclase (GC) within VSMCs [71, 72].

Earlier than the discovery of endothelium-derived NO, the lipid compound prostaglandin (PG) was identified in 1977 to be one of the first critical modulators of vascular function in both physiological and pathophysiological states [84]. Synthesized by two cyclooxygenase (COX) enzymes (COX1 and COX2) from arachidonic acid, the five primary PGS bind to specific PG receptors to either induce vasodilation [prostaglandin D₂ (PGD₂); prostaglandin I₂ (PGI₂)] or vasoconstriction [prostaglandin F₂α (PGF₂α); thromboxane A₂ (TXA₂)] or both [prostaglandin E₂ (PGE₂)] [85]. Similar to that in endothelium, expression of both COX1 and COX2 in PVAT bestows the ability to generate PGS, especially the vasodilatory PGI₂ [86]. Through binding to the prostacyclin receptor (IP) on VSMC, endothelium-derived PGI₂ stimulates G₄ subunit to activate adenylate cyclase for higher cyclic adenosine monophosphate (cAMP) production [87]. Subsequently, the adenosine triphosphate (ATP)-sensitive potassium channels (K₅ATP) and delayed-rectifier potassium channels (Kdr) of VSMC sense the increase in intracellular cAMP levels, resulting in their opening/activation, responsible for prostacyclin-mediated vasodilation [88]. However, although it was shown that PGI₂ from PVAT improves HFD-impaired endothelial function of ApoE⁻/⁻ mouse carotid artery [30], whether PVAT-derived PGI₂ follows the same mechanistic aspect as endothelium-derived PGI₂ remains is yet to be determined. In contrast, PVAT releases another lipophilic and heat-stable factor named methyl palmitate or palmitic acid methyl ester (PAME), which is associated with a more well-defined anti-contractile mechanism [89]. PVAT-derived PAME opens the voltage-gated potassium (Kᵥ) channels on VSMCs to promote vasorelaxation [33]. In SHR, both anti-contractile effect of PVAT and secretion of PAME were found to be diminished, indicating a possible role of PAME in the pathophysiology of hypertension [33]. More recent studies demonstrate that PAME could contribute to PVAT-related relaxations by activating KCNQ (Kᵥ7) channels in rat aorta but not in human mesenteric arteries [90].

The RAS of PVAT gives rise to the production of the heptapeptide Ang1-7, which serves as a vasodilator [91]. Particularly in the aortae and mesenteric arteries of humans and rodents, PVAT expresses the main RAS components, including angiotensinogen, angiotensin-converting enzyme (ACE), ACE2, renin, (pro)renin receptor, aldosterone, angiotensin II type 1 (AT₁), and angiotensin II type 2 (AT₂) [10, 92]. The RAS components of PVAT enable the conversion of Ang II to Ang1-7 via ACE2 [10], the relaxing factor that induces NO release through activating eNOS in endothelial cells [93]. Therefore, imbalanced release of Ang II and Ang1-7 from PVAT is closely related to the pathophysiology of vascular dysfunction and hypertension [94].

Apart from PVRFs, PVAT also produces PVCFs to modulate vasoconstriction. Imbalance between PVRFs and PVCFs deteriorates vascular function, which is often observed in pathological conditions such as obesity and hypertension [95]. Expressed by PVAT, the PVCF chemerin executes the chemerin-axis by docking to the primary chemerin receptor 23 (ChemR23) on VSMCs, leading to augmented...
vasoconstriction, particularly in obesity [96]. In addition, nor-
epinephrine (NE) released by PVAT also accounts for the
enhanced vasoconstriction [17]. In 2014, Ayala-Lopez et al.
showed that the non-sympathetic components within PVAT
microenvironment might supply catecholamines in a
tyramine-sensitive manner, causing arterial contraction [97].
Later in 2015, the same group provided additional experi-
tmental evidence to suggest that PVAT adipocyte expresses organic
cation transporter 3 (OCT3) to serve as the prime candidate
transporter, responsible for the uptake of NE into PVAT [97].
In other words, the local stores of NE (as catecholamine) in
PVAT adipocyte contribute to the arterial contraction [97].
Owen et al., through comparative proteomic analyses on cor-
monary PVAT between lean and obese swine, uncovered that
increased contractile effects of obese coronary PVAT are as-
associated with the alterations in the PVAT proteome, particu-
larly the protein calpastatin encoded by the calpastatin
(CAST) gene [98]. In the same study, ex vivo verification
shows that coronary adipose-derived calpastatin dose-
dependently increases contractions of swine coronary arteries
in the presence of PVAT [98], providing hints that calpastatin
might be a novel PVCF. Moreover, PVAT adipocytes also
generate ROS, specifically superoxide anion (O$_2^\cdot$), by nicot-
inamide adenine dinucleotide phosphate (NAD(P)H) oxidase
similar to endothelial cells [99]. Through the activation of
attractive enzyme and mitogen-activated protein kinase
(MAPK)/extracellular signal-regulated kinase (ERK) path-
way, O$_2^\cdot$ was found to be the augmenting factor of arterial
contractile response in rat superior mesenteric artery upon
electric field stimulation (EFS) [100].
Notably, PVAT secretes another critical subtype of
vasoregulatory candidates, namely adipokines including
adiponectin, leptin, TNF-α, and IL-6. Adiponectin is an abun-
dant adipocyte-derived plasma protein which is reported to
elicit vasoprotective benefits influencing the function of near-
ly all cell types within the vessel wall [101]. Basically,
adiponectin exerts protective effects on endothelium by acti-
vating the AMP-activated protein kinase (AMPK)/extracellular signal-regulated kinase (ERK) path-
way, O$_2^\cdot$ was found to be the augmenting factor of arterial
contractile response in rat superior mesenteric artery upon
electric field stimulation (EFS) [100].
Adipocytokines, referred to the constellation of both
adipokines and inflammatory cytokines, are important candi-
dates for maintaining the metabolic homeostasis of healthy
subjects. Deficiencies in these factors, either owing to adipo-
cyte dysfunction or excess adiposity, are intimately correlated
with the pathogenesis of multiple diseases related to obesity,
especially CVDs [115]. PVAT secretes an array of
adipocytokines, including adiponectin, leptin,
adrenomedullin, vascular endothelial growth factor (VEGF),
angiotensinogen, plasminogen activator inhibitor-1 (PAI-1),
resistin, omentin, apelin, adipin, agouti, acylation stimulation
protein (ASP), insulin-like growth factor-1 (IGF-1), secreted
frizzled-related protein 5 (SFRP5), TNF-α, and various inter-
leukins (e.g., interleukin 1 (IL-1), IL-6) [17, 115, 116]. Not
only these factors play an autocrine role in the metabolism of
PVAT adipocyte itself, they also carry out paracrine/endocrine
function to regulate other cellular processes.
In addition to the beneficial effect on vascular tone, adiponectin exerts many other vasculoprotective and angio-
genic properties. In terms of ischemia, adiponectin improves
angiogenic repair in adiponectin-knockout (KO) mice by ac-
tivating AMPK signaling in ischemic adductor muscle [117].
In addition, another study using adiponectin-KO mice showed
that adiponectin suppresses the neointimal thickening after
artery injury [118]. Furthermore, adiponectin performs anti-
inflammatory action by inhibiting the production of cysteine-
X-cysteine (CXC) receptor 3 chemokine ligands in
macrophages and by reducing the recruitment of T lymphocytes in atheroma using apoE/adiponectin double-deficient (apoE−/− APN−/−) mice [119]. Similarly, leptin also contributes to other aspects of cardiovascular system. Structurally similar to the helical cytokine family, leptin acts upon different immune cells, including monocytes/macrophages, T cells, and neutrophils to induce the release of inflammatory cytokines like TNF-α and IL-6, promoting vascular inflammation [120, 121]. Another study uncovered that via ERK1/2 and nuclear factor kappa-light-chain-enhancer of activated B cell (NF-κB) pathway, leptin can expedite VSMC proliferation, which aggravates arterial intimal thickening and vascular remodeling [122]. Furthermore, PVAT also expresses the angiogenic factor VEGF, which promotes the vasculogenesis and angiogenesis of endothelium, hematopoiesis of stem cells, and migration of monocytes/macrophages [123]. VEGF was shown to induce BAT-like phenotype in WAT in vivo [124], which accounts for the BAT-like properties of PVAT in an autocrine/paracrine manner. These experimental evidences shed light on the importance of PVAT, which acts as an important source of adiponectin, leptin, and VEGF apart from BAT and WAT.

The multiple PVAT-derived adipokines are crucial in maintaining the homeostasis of cardiovascular system by endocrinal regulation of different cell types. For instance, resistin promotes SMC proliferation and upregulates mRNA abundance of fatty acid-binding protein in endothelial cells to affect blood pressure [125]. Meanwhile, visfatin is considered one of the important VSMC growth factors via nicotinamide mononucleotide (NMN)-mediated ERK1/2 and p38 signaling [126], whereas omentin suppresses neointimal formation after arterial injury, myocyte apoptosis, and VSMC proliferation via AMPK-dependent signaling [127]. Apelin is crucial in modulating cardiac development, vasomotor tone, and angiogenesis [128], and IGF-1 exerts cardioprotective effects by inhibiting oxidative stress and apoptosis of cardiomyocytes [129]. PVAT-derived angiotensin is the critical raw material for RAS to synthesize Ang II, which induces gene reprogramming or necrosis in cardiac myocytes, and upregulation of fibrosis-associated genes in cardiac fibroblasts during cardiac dysfunction [130]. During obesity, high circulating level of adipose tissue-derived PAI-1 potentially stabilizes the fibrin matrix by suppressing plasminogen-mediated fibrinolysis to contribute to atherosclerotic plaque development and/or to promote the uptake of low-density lipoprotein (LDL) into lesion [131].

In healthy subjects, PVAT derives numerous anti-inflammatory adipocytokines, such as adiponectin, SFRP5, and adrenomedullin [11, 132]. Adiponectin, through binding to the COOH terminal of adiponectin receptor (AdipoR) of monocytes/macrophages, activates the AMPK phosphorylation to suppress I kappa B kinase (IKK)-NF-κB pathway, which hinders pro-inflammatory cytokine production to reduce the risk of acute myocardial infarction and atherosclerosis [133]. SFRP5 exerts an antagonistic effect against wingless-related MMTV integration site 5A (Wnt5a) signaling, in which Wnt5a exerts pro-inflammatory effects on endothelial cells and pro-atherogenic effect in aortic regions [120, 134]. Meanwhile, the bioactive peptide adrenomedullin was shown to combat inflammation by inhibiting the release of pro-inflammatory cytokines (IL-6, TNF-α, and interleukin 1β (IL-1β)) from lipopolysaccharide (LPS)-activated macrophages [132, 135]. In contrast, dysfunctional PVAT derives multiple pro-inflammatory adipocytokines, including monocyte chemotactic protein-1 (MCP-1), leptin, TNF-α, IL-1β, and IL-6 [136]. During obesity, increased fat mass is associated with the alterations in cellular composition, metabolome, and dysregulated adipocytokine secretome, characterized by dysfunctional adipose tissue [137]. In obesity, dysregulated adipocytes including perivascular adipocytes express classical macrophage features, characterized by a secretome of elevated pro-inflammatory and reduced anti-inflammatory adipocytokine contents (e.g., adiponectin, SFRP5) [136, 138]. Besides, these pro-inflammatory adipocytokines are responsible for prompting a chronic low-grade inflammation state, endothelial cell proliferation, microvascular remodeling, recruitment of macrophages (CD68+ cells) and T cells to atherosclerotic lesions, and polarization of macrophages towards M2 phenotype during atherosclerotic progression [11, 139].

miRNAs

The small non-coding miRNAs are important guide molecules in RNA silencing of gene expression [140]. miRNAs are crucial in regulating adipogenesis (formation of adipocytes), metabolic homeostasis, and endocrine functions of adipocytes [141]. Many miRNAs have been identified to be differentially regulated during adipogenesis in human and murine, including let-7c, miR-143, miR-210, miR-221, miR-27, and miR-30a-e [142]. Notably, obesity alters the expression profile of miRNAs in adipose tissue, influencing the progression of inflammation in human adipose tissue [141, 142]. For instance, the expressions of miR-26b, miR-132, and miR-155 are associated with the number of macrophages infiltrating the fat depot [143]. During obesity, the expression of miR-132 is down-regulated and its expression level is related to the activation of NF-κB signaling and transcription of MCP-1 and interleukin 8 (IL-8) [141, 144]. More importantly, in addition to the adipogenesis and modulation of inflammation state of adipocytes themselves, different studies reported that adipose tissue is capable of secreting circulating miRNAs (cir-miRNAs) to the bloodstream for endocrine functions. The cir-miRNAs might be trapped within microvesicles or exosomes [27, 29]. Collectively termed as extracellular vesicles, microvesicles (around 100 nm to 1 μm in diameter) and exosomes (around 40–100 nm in diameter) are of different sizes and origins [145].
In 2017, Thomou et al. reported that mice with adipose tissue-specific knockout of miRNA-processing enzyme Dicer (ADicerKO) display a significant decrease of circulating exosomal miRNAs and stated that cir-miRNAs should be defined as a previously undescribed form of adipokine [29]. Earlier in 2010, Ogawa et al. provided in vitro data that 3T3-L1 adipocyte-derived microvesicles contain 143 miRNAs in which most of them are adipocyte-specific and that these miRNA-containing microvesicles could be transported into cultured macrophages [146]. In the same study, miRNA-containing microvesicles were identified to be present in rat serum in vivo [146]. With close proximity to the circulatory system, it is therefore reasonable to hypothesize that PVAT might be one of the closest sources of adipose tissue-derived cir-miRNAs, encapsulated in either exosomes or microvesicles, in the endocrine regulation of other tissues. Moreover, Thomou et al. also reported that Dicer-knockout not only modulates fundamental functions of adipocytes like whitening of BAT, but also influences other tissues altering circulatory lipids, glucose uptake, and insulin resistance [29, 147]. These studies might shed light on the therapeutic potential of targeting cir-miRNAs in cardiovascular complications concerning abnormal energy intake and lipid metabolism.

PVAT Innervation

Little is known about the effects of PVAT on nervous systems controlling blood vessels. A recent review in 2014, by Bulloch and Daly, highlighted our poor understanding of the link between PVAT and the autonomic nervous system, or other nerves, that are involved in controlling the vasculature [25]. In fact, the innervation of PVAT was first demonstrated in 1970, when Diculescu and Stoica produced a set of Falk fluorescence plates demonstrating a clear innervation of perivascular fat in the rat mesenteric artery [148]. However, it is only recently that the interest to investigate neurotransmission in PVAT has been revived.

Blood vessels, especially resistant vessels, receive multiple perivascular innervations from autonomic system (sympathetic nerves) and non-adrenergic non-cholinergic (NANC) neurotransmissions, including sensory nerves, peptidergic innervations [calcitonin gene-related peptide (CGRP) and substance P], and nitrergic innervation. In addition, co-transmission concept that includes purinergic signaling and NPY also mediates vascular tone. Purinergic signaling arises from both sympathetic and sensory nerves while NPY is the second main neurotransmitter co-released from sympathetic nerve terminals [149]. Due to limited availability of research articles on neuronal expression and activity within PVAT, the present article can only review sympathetic and sensory neurotransmissions in PVAT. Both sympathetic and sensory nerves are well-known as the key players in vascular regulation and interact reciprocally [149]. For instance, activation of sensory nerves reduced adrenergic neurotransmission via pre-junctional inhibition and treatment with CGRP or SP decreased the amplitude of neurogenic-evoked vasoconstriction [150, 151]. Conversely, capsaicin-induced transient receptor potential cation channel subfamily V member 1 (TRPV1) desensitization and inhibition of CGRP receptors enhanced neurogenic vasoconstriction [152, 153].

Sympathetic Nervous System Innervation of Adipose Tissue

The innervation of BAT by the sympathetic nervous system (SNS) has long been recognized both at the level of blood vessels and also directly on adipocytes [154]. SNS innervation plays a critical role in regulating non-shivering thermogenesis in rodents by controlling the release of noradrenaline (NA) from sympathetic nerve terminals, which consequently stimulates β3-adrenoceptors that turns on a cascade of intracellular events ending in activation of UCP1 and triggering BAT thermogenesis [155, 156]. Investigation using histofluorescence, electron microscopy, and unilateral denervation model verified the sympathetic innervation of BAT [155, 157]. Further examination with retrograde viral transneuronal tract tracer, pseudorabies virus, injected into the central sympathetic outflow, revealed that circuits ultimately terminate in BAT, indicating that the SNS outflow directly originates from the brain [155].

Various experimental approaches, including neurochemical (NE turnover), neuroanatomical (viral tract tracing), and functional (sympathetic denervation-induced blockade of lipolysis) studies have revealed SNS innervation in WAT [158–160]. In WAT, the SNS is the principal initiator of lipolysis in mammals [161]. It has been demonstrated that the sympathetic nervous system plays a role in modulating lipolysis in white adipose tissue and the degree of lipolysis appears to be determined by the relative expression of adipose adrenoceptors [158]. Adipocytes express receptors for the sympathetic co-transmitters NPY and ATP (NPY receptors and purinoceptors, respectively) and also express muscarinic receptors and receptors for peptides including angiotensin II and SP [162]. Four adrenoceptor subtypes, α2-, β1-, β2-, and β3-adrenoceptors, exist in WAT [163–165], in which all beta (β1-, β2-, and β3-) adrenoceptors stimulate lipolysis while α2-adrenoceptors inhibit the process [166]. The SNS innervation in WAT also plays a role in the control of lipid proliferation [158, 167]. It has been shown that sympathetic denervation of WAT in vivo stimulates fat cell proliferation [160].

SNS Innervation of PVAT

In nearly every vascular bed studied across different animal species, the expression of sympathetic nerves has been shown...
and it accounts for the largest proportion of innervation in the resistance vasculature [149]. Sympathetic nerves mainly regulate medium and small arteries, and innervation is sparser in large conduit arteries [168]. It has been reported that vascular responses to sympathetic nerve activity (SNA) can vary, depending on the content and composition of vesicles released from specific axon varicosities [169, 170], the size and location of vessel branches within resistance networks [171, 172], and the frequency and firing pattern of action potentials [173].

In 2011, Dashwood and Loesch showed that PVAT of human saphenous vein receives direct sympathetic innervation using immunostaining technique [174]. More recently, Bulloch and Daly also provided evidence of sympathetic innervation in PVAT, of mouse mesenteric arteries, using immunofluorescence techniques [25]. Adipocytes were observed to be innervated by sympathetic nerves, with mast cells commonly located along the nerves [148]. The same study also found that BAT comprises more nerve fibers compared to WAT [148]. Consistently, another study found that adrenergic nerves innervated only 2–3% of all WAT isolated from rats mesentery, epididymis, omentum, and subcutis which were fed, fasted or fasted, and then refed [175]. Although it is becoming more apparent that sympathetic nerves are distributed within PVAT, however, its influence on vasoregulation is not well-defined yet.

In the seminal study of PVAT in 1991, the potential involvement of sympathetic nerves in modulating contractile response to electrical field stimulation has been revealed [32]. Electric field stimulation (EFS) produced a frequency-dependent contraction in intact rat aortae but no response observed in cleaned tissues [32]. The authors postulated that this was most likely due to the presence of sympathetic nerves in the PVAT [32]. In 2006, Gao et al. revisited the neurogenic contractile response in tissues with PVAT and their studies were carried out in rat mesenteric arteries [100]. The group produced a similar observation to that of Soltis and Cassis, in which PVAT augmented the arterial contractile response to perivascular nerve stimulation [32, 100]. This was shown to occur through the production of superoxide mediated by NAD(P)H oxidase and involved activation of tyrosine kinase and MAPK/ERK pathways [100]. In 2010, Lu et al. further explored a pro-contractile property of PVAT on perivascular nerves by providing evidence for the presence of angiotensin II in mesenteric PVAT [176]. This PVAT-derived compound was suggested to potentiate EFS-evoked neurogenic contractile responses in isolated rat mesenteric arteries, consistent with previous observations that angiotensin II enhances sympathetic neurotransmission through pre- and post-junctional mechanisms [177, 178].

Despite the majority of studies showing that sympathetic activation in PVAT promotes vasoconstriction in different vessels [32, 100, 176], however, there are few recent studies that contradict the role of PVAT-derived sympathetic nerves in vascular tone regulation. Ayala-Lopez et al. demonstrated that removal of PVAT did not reduce response of EFS stimulus at 20 Hz of rat aortae; however, the presence of PVAT in rat superior mesenteric artery potentiated a 20-Hz-induced contraction [97]. The authors also showed that PVAT comprises functional catecholamines and which are independent of sympathetic nerves and tyramine-sensitive [97]. In a more recent publication, the same group also found that PVAT of human splanchnic blood vessels contain elements of an adrenergic system with capabilities of synthesis and storage of catecholamines, which may influence vascular tone [179]. However, how PVAT catecholamines would be stimulated or released potentiates EFS-evoked neurogenic contraction [180]. In contrast to previous studies, the group showed that the presence of PVAT potentiated vasoconstriction in normotensive and hypertensive rats [181]. The group demonstrated that PVAT exhibited inhibitory influence on the contractions to endogenous norepinephrine released from arterial sympathetic nerves during EFS in superior mesenteric artery isolated from normotensive Wistar-Kyoto rats (WKY), which is in line with a recent study [180]. However, the anti-contractile effect against sympathetic-induced vasoconstriction was abolished in spontaneous hypertensive rats [181]. In contrast, the abdominal aorta with intact PVAT elicited larger contractions to EFS and tyramine when compared to the aortae after removing PVAT [181]. The authors attributed that the difference in the modulatory effect of PVAT on adrenergic contractions between abdominal aortae and superior mesenteric arteries might be due to the endogenous NE of PVAT [181].

Accumulating data on the effect of sympathetic neurotransmission in PVAT marks discrepancy. The diversity of experimental conditions, species, and vessels used may account for this contradictory observations. As for experimental conditions, many studies used different parameters (voltage, frequency, duration, and pulse) for studying direct adrenergic activation. Some studies used supramaximal voltage, although majority of studies used nerve blockers such as guanethidine and/or tetrodotoxin to verify nerve mediation in EFS-evoked responses. It has been proposed that greater voltage potentiates EFS-enhanced vasoconstriction in PVAT-intact preparations, probably due to generation of superoxide anions [180]. Furthermore, certain groups carried out experiments under...
basal condition while some other groups conducted experiments under raised tone, using different agents. The conflicting data should be addressed and the role of sympathetic innervation in PVAT should be elucidated as it may represent a novel target in the treatment of cardiovascular diseases.

**The Interaction Between Sympathetic Nerves and PVAT-Derived Mediators**

PVAT is well-recognized as a source of numerous vasoactive compounds. It therefore holds promise as a novel therapeutic target. Despite this, information on the link between PVAT-derived mediators and the neurovascular system is sparse. To date, very few in vitro studies that have investigated specifically on the relationship between PVAT-derived nerves and PVAT mediators [180, 182], although there are substantial number of studies which have examined the non-PVAT-specific interaction between sympathetic activation and adipokines. Receptors for adrenergic system and its co-transmission have been detected in adipocytes and stimulation of these receptors modulate adipocytes physiology (e.g., lipolysis and lipogenesis) and contents [162]. Hence, it is postulated that sympathetic innervation in PVAT modulates PVAT mediator release and integral for normal vascular function as well as pathophysiology and vice versa. Indeed, our understanding on the complex interaction between PVAT-derived nerves and PVAT-derived factors is at its infancy, despite it has huge potential in modulating vascular tone. A challenge to scrutinize the crosstalk includes the extremely short duration of neurotransmission and the involvement of non-neuronal effect resulting from the overstimulation of SMCs. In addition, technique to elucidate the PVAT-specific interaction in vivo proves to be challenging and still have not been developed yet.

Recently, it has become apparent that the sympathetic system is a key regulator of leptin production in WAT [183]. Sympathomimetic amines and cold exposure or fasting (which results in sympathetic stimulation in WAT) decrease leptin gene expression in the tissue and thus leptin production [183]. Furthermore, it has been shown that the β3-adrenoceptor is involved in inhibiting insulin-stimulated leptin secretion from isolated rat adipocytes [184], and it has also been postulated that the sympathetic system might contribute to supporting an inhibitory action on leptin synthesis [183]. Conversely, sympathetic blockade often increases circulating leptin and leptin gene expression [183]. In turn, leptin regulates arterial pressure by enhancing sympathetic nerve activity to brown adipose tissue, kidney, and other tissues [185]. Acceleration of sympathetic activity is a hallmark of obesity. In obese patients, it has been shown that cytokines derived from adipocytes such as leptin, TNF-α, and IL-6 mediate sympathetic activation [186]. Some studies indicated that leptin acts both centrally and peripherally to potentiate the sympathetic nervous system, including enhancing catecholamine synthesis in the adrenal medulla [187, 188], which subsequently activate the renal sympathetic nerves, hence increase blood pressure. Resistin, a pro-contractile adipokine, acts directly in the central nervous system to influence the sympathetic nerve activity [189]. There is growing evidence that resistin may have complex interactions with leptin [189, 190]. Both of these adipokines synergistically excite sympathetic nerves innervating cardiovascular organs but could antagonize each other’s actions on BAT, in which resistin inhibits BAT activity and vice versa [189].

Adiponectin, a protective adipokine, has been shown to be regulated by adrenergic system. Imai and co-researchers demonstrated that sympathetic nervous system suppresses serum adiponectin levels and adiponectin mRNA expression in mice subcutaneous, epididymal, and mesenteric WAT in vivo [191], and the regulation differs among WAT depots of mice. In their study, it was shown that cold exposure suppresses serum adiponectin levels through sympathetic nerve activation [191]. Consistently, in healthy male volunteers, exposure to cold for 2 h activated sympathetic nerves, which consequently reduced adiponectin release [192]. Nonetheless, subcutaneous adipokine gene expression was unaltered [192]. The same study found that sympathetic stimulation triggered MCP-1 release [192]. On the contrary, a very recent study showed that direct sympathetic stimulation in PVAT of mice mesenteric arteries in vitro enhanced the release of adiponectin via β3-adrenoceptor activation [180].

IL-6 is a pro-inflammatory cytokine shown to be secreted in higher concentrations from PVAT compared with other fat depots and potentially has a role in promoting arterial stiffness [193, 194]. An in vivo study by De Luigi et al. showed that sympathectomy increased lipopolysaccharide-induced IL-1β and IL-6 messenger RNA in rat adrenals and spleen and concluded that sympathetic nervous system denervation enhances the synthesis and production of peripheral IL-1β and IL-6 by central lipopolysaccharide [195]. Sympathetic neurons have also been shown to stimulate production of IL-6 in vitro using cell culture [196]. MCP-1, another pro-inflammatory cytokine, has been reported to be rapidly expressed by sympathetic ganglion neurons following axonal injury [197].

**Sensory Innervation in Adipose Tissue**

Sensory nerves are abundant in WAT [158, 160]. Sensory innervation of WAT was first shown neuroanatomically using an anterograde tract tracer, true blue, which resulted in labeled neurons in the dorsal root ganglia (DRG) [198]. Further experiments including histology and a transneuronal viral tract tracer, the H129 strain of herpes simplex virus-1 (HSV) [199], convincingly corroborated the existence of CGRP and SP containing nerves within WAT. BAT also has significant
sensory innervation, as revealed by immunohistochemical staining for CGRP and SP [154, 200].

There is accumulating evidence that BAT has marked sensory innervation, as shown by immunohistochemical markers of sensory neuropeptides such as CGRP and SP [155]. Denervation of sensory nerves in BAT results in general decreases in BAT growth and protein content, mitochondrial content such as cytochrome oxidase activity, and thermogenic capacity, such as UCP1 content [201, 202]. Collective data obtained from different experimental protocols including anterograde viral tract tracer [198], co-culture of DRG cell and adipocytes, and immunohistochemistry staining strongly indicate that WAT is innervated by sensory nerves [203]. Recently, Murphy et al. showed endogenous leptin secreted from WAT activates spinal sensory nerves innervating Siberian hamster brain in a paracrine manner [204]. Despite the innervation and feedback loops of sensory nerves that have been recognized in WAT [205], the significance of the innervation is still poorly understood and warrants further exploration.

**Sensory Neurotransmission in PVAT**

Evidence has accumulated that NANC nerves play important roles in regulating vascular tone [206]. In NANC neurotransmission, sensory nerves play a vital role in vasoregulation and generally cause vasodilatation [206, 207]. Sensory nerves demonstrate physiological antagonism of sympathetic vasoconstriction [208] and also possesses both anti-dromic and orthodromic conduction; thus, this allows their participation in local axon reflexes independent of efferent signaling from the cell body [209]. CGRP, a potent vasodilator, has been recognized as the primary neurotransmitter of sensory nerves while SP is a cotransmitter [207, 210]. CGRP is a 37-amino acid neuropeptide that is primarily localized to C and Aδ sensory fibers and has two major forms, α and β [211]. αCGRP is predominantly expressed in the nervous system while β-CGRP is primarily expressed in the enteric sensory system [212]. A recent study has provided solid evidence that sensory nerves are intimately linked to the sympathetic and angiotensin signaling systems [211]. In CGRP knockout mice, enhanced hypertension and vascular remodeling/inflammatory changes in an angiotensin II-induced hypertension model have been demonstrated [213]. Hence, this has created a concept that sensory nerves appear to play a protecting role against the adverse effects associated with the cardiovascular disturbance.

In vascular arena, PVAT has now has become the subject of intense investigation as it involves in cardiovascular pathophysiological conditions. In spite of the extensive research on PVAT, surprisingly, expression and role of sensory nerves in PVAT have not been described previously. It was thought that sensory nerves which involved in blood vessel regulation were only confined at the adventitia and relaxation responses to EFS in rat isolated mesenteric artery were credited to myogenic tone or dependent on an intact endothelium [214, 215]. Nonetheless, it is very intriguing to find out that there is a mismatch of EFS experiment outcomes for isolated rat mesenteric arterial bed and rat isolated mesenteric artery. Furthermore, evidence of sensory-induced vasorelaxation in other isolated arteries is limited [182]. In rat PVAT-intact mesenteric artery beds, EFS elicited robust sensory neurogenic relaxation responses but these responses were markedly reduced in PVAT-denuded mesenteric artery beds or abolished in clean rat mesenteric artery [182]. The discovery made by Abu Bakar et al. on the expression of sensory nerves within PVAT and functional sensory nerves that are critically dependent on PVAT has orientated our understanding on the role of sensory nerves [216]. PVAT-denuded vessels that are normally used in conventional vascular experiments have led to a postulation that sensory nerves are not involved in vasodilatation of rat mesenteric artery; however, this concept has been refuted by the recent finding [182]. On contrary to EFS-induced sensory stimulation, it is interesting to note that PVAT removal does not totally eradicate EFS-evoked frequency-dependent vasoconstriction (sympathetic activation) [180, 181], although some studies demonstrated significant reduction of EFS-evoked sympathetic vasoconstriction in clean vessels [32, 100, 176]. In addition, while many studies have shown extensive sensory innervation at the adventitia of clean vessels [182, 207, 217], however, it is unclear why vasodilatation cannot be demonstrated in the absence of PVAT. The data however further corroborates that PVAT plays a crucial role in sensory-induced vasodilation.

In comparison to sympathetic nerves which have been located in PVAT in 1970 [148], it is only recently that sensory nerve innervation has been demonstrated in PVAT [182]. A double staining protocol with the presence of anti-CGRP and anti-protein gene product (PGP) 9.5 antibodies was applied to verify the observation [182]. The distribution of nerves was found to be more extensive in small arteries (second-order of mesenteric artery) compared to large arteries (superior mesenteric artery), which is consistent with EFS data which showed neurogenic relaxation responses to EFS were greater in second-order mesenteric artery compared to superior mesenteric artery [182]. Interestingly, cell bodies or neuronal somata were visualized in PVAT of rat mesenteric artery [182]. The observation is not in line with the traditional notion, in which cell bodies of CGRP were believed to be located only in DRG [218], and terminate peripherally on blood vessels and other tissues innervated by the sensory nervous system, and also centrally in laminae I/II of the dorsal horn of the spinal cord [219]. However, a more recent research using DNA sequence analysis to show 100% homology with the β-CGRP cDNA indicates that mRNA encoding β-CGRP is expressed in the vessel, exhibited the presence of adventitial neuronal somata in small rat mesenteric artery [220], which is consistent with...
the recent observation [182]. CGRP immunoassay study data further supports the existence of sensory nerves in PVAT layer [182].

Investigation to elucidate the interaction between PVAT-derived sensory nerves and PVAT-derived mediators has been attempted in the recent study [182]. The attempt has led to a development of a new technique which exclusively study the interaction between PVAT-derived nerves and PVAT-derived factors; tissues (mesenteric artery beds) in the presence or absence of PVAT were perfused under normal or low oxygenation, EFS was applied and samples (perfusates) were collected during EFS (very short period), and the samples were then subjected to multiplex assay for adipokines (adiponectin, leptin, IL-6, MCP-1, TNF-α, interleukin beta (IL-β), and total PAI-1 analysis [182]. Under standard oxygenation, only leptin level was shown to be elevated in PVAT-intact preparations [182], which suggests that there is a link between endogenous leptin and sensory nerves. Presumably, CGRP and/or other neurotransmitter(s) released from sensory nerves during EFS act at receptors on the adipocytes in PVAT to cause a release of leptin. Furthermore, exogenous leptin potentiated neurogenic-mediated relaxations in mesenteric arteries [182]. This observation is consistent with leptin’s effect in the cardiovascular system. Under normal conditions, leptin demonstrates vasorelaxing effect [221, 222]. The anti-contractile effect of leptin is achieved via both endothelial-dependent (through involvement of NO) and endothelial-independent mechanisms [223, 224]. It has been shown that leptin dilates canine small mesenteric arteries and veins by a mechanism involving endothelial release of nitric oxide [221]. Recently, the role of leptin secreted from WAT as a paracrine factor to activate spinal sensory nerves has been shown in Siberian hamsters [204]. A more recent publication shows that leptin receptors LepR are expressed on sensory neurons, and the deletion of leptin signaling in vagal afferent neurons results in hyperphagia and obesity [225]. Hence, the present data adds a new insight on the relationship between leptin and sensory nerves.

The release of leptin was virtually abolished by both PVAT removal and under conditions of low oxygen. In addition, low oxygen levels were shown to enhance inflammatory mediator, IL-6 release [182]. The observation highlights that the level of oxygen plays a role in mediating the release of some PVAT mediators. Moreover, acute hypoxia model that was employed in the study might be extrapolated for certain disorders, such as hypoxia in obesity, and can be exploited for studying the effect of PVAT on neurotransmissions under pathological conditions.

Future Perspectives—What Is Next?

The autocrine/paracrine/endocrine functions of PVAT have been elucidated by an abundance of experimental and clinical research. However, there still remain some major unanswered questions and emergent future directions about PVAT. In the first place, the true identity of ADRF still requires confirmation. Although certain studies pointed that H2S might potentially be the primary ADRF candidate of perivascular adipocytes [75], however, H2S might not be the universal ADRF since CSE inhibition does not diminish the anti-contractile effect in mouse aorta [79], unlike endothelium-derived NO which is the universal vasodilator of different species. Furthermore, there is data indicating that adiponectin is not the ADRF using an approach of utilizing adiponectin gene-deficient mice [226]. Another investigation provided clues that the deficiency of leptin receptors in the Zucker fa/fa rat showed no significant modification on the anti-contractile effect of PVAT, implying that leptin probably is not the ADRF [227]. Despite the unclear chemical nature of ADRF, a promising ADRF candidate should at least fulfill the requirement to mimic ADRF characteristic effects on K+ channels (i.e., it should be a potent opener of KCNQ and probably other K+ channels), as reviewed in 2012 and 2017 [6, 17]. Therefore, future studies need to explore the constellation of ADRF-activated KCNQ channels and other involved K+ channels and to identify the identity of ADRF with reference to the stated requirements using gene-silencing or knockout techniques.

In addition, more efforts are needed to perform comparative studies to dig out the similarities between the mechanisms of endothelium-induced and PVAT-induced relaxation, for the purpose of reductionism. For example, further experiments should be carried out to verify whether PVAT-derived PGI2 follows the same mechanistic aspect as endothelium-derived PGI2. Multiple rodent models are currently available, characterized by the reduction in the content of BAT and/or WAT (Table 2). However, the lack of report on the actual reduction of PVAT might limit the dependability of certain models such as transgenic skinny and FAT-ATAC mice [54, 56]. Hence, further verification on the PVAT content of the genetic engineered mice might extend the generality of PVAT studies.

In 2017, Thomou et al. provided experimental clues in hinting the novel endocrine regulatory approach of adipose tissue via cir-miRNAs [29]. The close proximity between PVAT and vascular tree provides sufficient suspects that PVAT might be one of the major sources of cir-miRNA factory. However, the field concerning PVAT-derived cir-miRNA is still largely undefined so we propose the following questions: (1) whether PVAT shares similar miRNA expression profile as BAT or WAT, (2) whether exosomes and microvesicles cir-miRNAs are the sole packaging approaches of cir-miRNAs for long-distance metabolic regulation, (3) what is miRNA profile of extracellular vesicles, and (4) how the onset and progression of CVDs are mediated by cir-miRNAs. According to the genome-wide comparative
expression studies between subcutaneous and coronary perivascular adipose tissue-derived adipocytes, a signature of 307 differentially expressed genes for cardiovascular homeostasis was identified [7]. It is of rationale to hypothesize that PVAT should have different miRNA expression profile and hence altered cir-miRNA expression profile. Apart from exosomal and microvesicular cir-miRNAs, whether adipose tissue generates other carriers for cir-miRNA packaging, such as microparticles, requires further confirmation. Previous study showed that adipocytes are able to release microparticles, which act as “find-me” signals to prompt macrophage migration [228], and therefore microparticles might be a third option of miRNA carrier. Past investigation focused on how the generation of fibroblast growth factor 21 is affected by the presence of cir-miRNAs [29]; therefore, future studies can concentrate more on the role of cir-miRNAs in cardiovascular complications such as endothelial dysfunction, coronary heart disease, and atherosclerosis.

Conclusions

Since the identification of anti-contractile effect of PVAT in 1991, more and more primary and clinical investigations unravel the roles of PVAT in addition to the vasoregulatory effect. Accompanied by the increasing rates of obesity worldwide, more scientists and clinicians are now aware of the pivotal endocrine and paracrine roles of adipose tissue in obesity-related cardiovascular events. More importantly, the close proximity between PVAT and vascular system facilitates the interaction between PVAT and vascular system. PVAT, through the production of numerous perivascular contracting/relaxing factors and adipocytokines, acts as an autocrine/paracrine/endocrine regulatory center for the homeostasis of cardiovascular system, sharing the status not less important than that single layer of endothelium. Furthermore, PVAT provides an interface for active PVAT-neuronal communications and may be a potential source of cir-miRNAs. Therefore, PVAT is a master endocrine organ, much more than a mechanistic support to the vasculature.

Author Contributions All the authors researched the data for the article, provided substantial contributions to discussions of its content, wrote the article, and edited/reviewed the manuscript before submission.

Funding Information The authors acknowledge funding from the Deutsche Forschungsgemeinschaft (DFG), Deutsche Akademische Austauschdienst (DAAD) (Germany-Hong Kong Joint Research Scheme), CUHK Direct Grant (4054373) and Hong Kong Research Grants Council (RUI/Imgegrant/gkh1415/0818/14ck).

Compliance with Ethical Standards

Competing Interests The authors declare no competing interests.

References

1. Ozen G, Daci A, Norel X, Topal G. Human perivascular adipose tissue dysfunction as a cause of vascular disease: focus on vascular tone and wall remodeling. Eur J Pharmacol. 2015;766:16–24.
2. Siegel-Axel DI, Häring HU. Perivascular adipose tissue: an unique fat compartment relevant for the cardiometabolic syndrome. Rev Endoer Metab Disord. 2016;17:51–60.
3. Gil-Ortega M, Somoza B, Huang Y, Gollasch M, Fernández-Alfonso MS. Regional differences in perivascular adipose tissue impacting vascular homeostasis. Trends Endocrinol Metab. 2015;26:367–75.
4. Heftzet-Sela S, Scherer PE. Adipocytes: impact on tumor growth and potential sites for therapeutic intervention. Pharmacol Ther. 2014;138:197–210.
5. Schäfer K, Drosos I, Konstantinides S. Perivascular adipose tissue: epiphenomenon or local risk factor? Int J Obes. 2017;41:1311–23.
6. Gollasch M. Vasodilator signals from perivascular adipose tissue. Br J Pharmacol. 2012;165:633–42.
7. Chatterjee TK, Aronow BJ, Tong WS, Manka D, Tang Y, Bogdanov VY, et al. Human coronary artery perivascular adipocytes overexpress genes responsible for regulating vascular morphology, inflammation, and hemostosis. Physiol Genomics. 2013;45:697–709.
8. Victorio JA, Fontes MT, Rossoni LV, Daval AP. Different anti-contractile function and nitric oxide production of thoracic and abdominal perivascular adipose tissues. Front Physiol. 2016;7:1–10.
9. Hildebrandt S, Stümmer J, Pfeifer A. PVAT and its relation to brown, beige, and white adipose tissue in development and function. Front Physiol. 2018;9:9–10.
10. Gálvez-Prieto B, Bolbrinker I, Stucchi P, de las Heras A, Merino B, Arribas S, et al. Comparative expression analysis of the renin-angiotensin system components between white and brown perivascular adipose tissue. J Endocrinol. 2008;197:55–64.
11. Lian X, Gollasch M. A clinical perspective: contribution of dysfunctional perivascular adipose tissue (PVAT) to cardiovascular risk. Curr Hypertens Rep. 2016;18:82.
12. Wu J, Boström P, Sparks LM, Ye L, Choi JH, Giang AH, et al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell. 2012;150:366–76.
13. Brown NK, Zhou Z, Zhang J, Zeng R, Wu J, Eitzman DT, et al. Perivascular adipose tissue in vascular function and disease: a review of current research and animal models. Arterioscler Thromb Vasc Biol. 2014;34:1621–30.
14. Almabrouk TAM, Ewart MA, Salt IP, Kennedy S. Perivascular fat, AMP-activated protein kinase and vascular diseases. Br J Pharmacol. 2014;171:595–617.
15. Villacorta L, Arbor A, Campus N, Arbor A. The role of perivascular adipose tissue in vasconstriction, arterial stiffness, and aneurysm. Horm Mol Biol Clin Investig. 2015;21:137–47.
16. Li Y, Mihamara K, Saiedeedine M, Krawetz A, Lai D, Li H, et al. Perivascular adipose tissue-derived relaxing factors: release by peptide agonists via proteinase-activated receptor-2 (PAR2) and non-PAR2 mechanisms. Br J Pharmacol. 2011;164:1990–2002.
17. Gollasch M. Adipose-vascular coupling and potential therapeutic strategies. Annu Rev Pharmacol Toxicol. 2017;57:417–36.
18. Szasz T, Webb RC. Perivascular adipose tissue: more than just structural support. Clin Sci. 2014;122:706–21.
19. Henrichet E, Juge-Aubry CE, Pernot A, Pache JC, Velebit V, Dayer JM, et al. Production of chemokines by perivascular adipose tissue: a role in the pathogenesis of atherosclerosis? Arterioscler Thromb Vasc Biol. 2005;25:2594–9.
20. Kralova Lesna I, Kralova A, Cejkova S, Fronek J, Petras M, Sekerkova A, et al. Characterisation and comparison of adipose tissue macrophages from human subcutaneous, visceral and perivascular adipose tissue. J Transl Med BioMed Central. 2016;14:1–9.

21. Horimatsu T, Kim HW, Weintraub NL. The role of perivascular adipose tissue in non-atherosclerotic vascular disease. Front Physiol. 2017;8:1–11.

22. Corselli M, Crisan M, Murray IR, Scholes J, Codrea F, et al. Identification of perivascular mesenchymal stromal/stem cells by flow cytometry. Cytom Part A. 2013;80A:1–7.

23. Chen Q, Shou P, Zheng C, Jiang M, Cao G, Yang Q, et al. Fate decision of mesenchymal stem cells: adipocytes or osteoblasts? Cell Death Differ. 2016;23:1128–39.

24. James AW, Zara JN, Zhang X, Askarianam A, Goyal R, Chiang M, et al. Perivascular stem cells: a prospectively purified mesenchymal stem cell population for bone tissue engineering. Stem Cells Transl Med. 2012;1:510–9.

25. Bulloch JM, Daly CJ. Autonomic nerves and perivascular fat: interactive mechanisms. Pharmacol Ther. 2014;143:61–73.

26. Burnstock G. Purinergic signalling in endocrine organs. Purinergic Signal. 2014;10:189–231.

27. Ge Q, Brichard S, Xi Y, Li Q. MicroRNAs as a new mechanism regulating adipose tissue inflammation in obesity and as a novel therapeutic strategy in the metabolic syndrome. J Immunol. Res. 2014;10:40.

28. Ge Q, Gérard J, Noël L, Scroeny I, Brichard SM. MicroRNAs regulated by adiponectin as novel targets for controlling adipose tissue inflammation. Endocrinology. 2012;153:5285–96.

29. Thomou T, Morikawa M, Dreyfuss JM, Konishi M, Sakaguchi M, Wolf®tm C, Jäger H, et al. Adipose-derived circulating miRNAs regulate gene expression in other tissues. Nature. 2017;542:450–5.

30. Chang L, Villacorta L, Li R, Hamblin M, Xu W, Dou C, et al. Loss of perivascular adipose tissue upon PPPARγ deletion in smooth muscle cells impairs intravascular thermoregulation and enhances atherosclerosis. Circulation. 2012;126:1067–78.

31. Lu C, Su LY, Lee RMKW, Gao YJ. Alterations in perivascular adipose tissue structure and function in hypertension. Eur J Pharmacol. 2011;656:68–73.

32. Solitis EE, Cassis LA. Influence of perivascular adipose tissue on rat aortic smooth muscle responsiveness. Clin Exp Hypertens. 1991;13:277–96.

33. Lee YC, Chang HH, Chiang CL, Liu CH, Yeh JI, Chen MF, et al. Role of perivascular adipose tissue-derived methyl palmitate in vascular tone regulation and pathogenesis of hypertension. Circulation. 2011;124:1160–9.

34. Takaoka M, Gao YJ, Ding L, Su LY, An WS, et al. Irisin improves perivascular adipose tissue dysfunction via regulation of the heme oxygenase-1/adiponectin axis in diet-induced obese mice. J Mol Cell Cardiol. 2016;99:188–96.

35. Xia N, Horke S, Habermeier A, Closs EI, Reifenberg G, Gerike A, et al. Uncoupling of endothelial nitric oxide synthase in perivascular adipose tissue of diet-induced obese mice. Arterioscler Thromb Vasc Biol. 2016;36:78–85.

36. Araujo HN, Victório JA, Valgas da Silva CP, Sponton ACS, Vettorazzi JF, de Moraes C, et al. Anti-contractile effects of perivascular adipose tissue in thoracic aorta from rats fed a high-fat diet: role of aerobic exercise training. Clin Exp Pharmacol Physiol. 2017;45:293–302.

37. Araujo HN, Valgas Da Silva CP, Sponton ACS, Clerici SP, Davel AP, Antunes E, et al. Perivascular adipose tissue and vascular responses in healthy trained rats. Life Sci. 2015;125:79–87.

38. Manka D, Chatterjee TK, Stoll LL, Basford JE, Konaniah ES, Arking DE, et al. Perivascular adipose tissue and vascular remodeling. Circ Res. 2009;105:906–11.

39. Ying R, Chen J, Yang Y, Zhang H, Chen Y, Wang J. Transplanted perivascular adipose tissue promotes destabilization of atherosclerotic plaque in apolopoprotein E-deficient mice. J Am Coll Cardiol Found. 2017;69:2034.

40. Moitra J, Mason MM, Olive M, Krylov D, Gavrilova O, Marcus-Samuels B, et al. Life without white fat: a transgenic mouse. Genes Dev. 1998;12:12168–81.

41. Han F, Zhang Y, Shao M, Mu Q, Jiao X, Hou N, et al. C1q/TNF-related protein 9 improves the anti-contractile effects of perivascular adipose tissue upon PPARγ deletion in smooth muscle cells. Physiol. 2017;45:2329–302.

42. Takemori K, Gao YJ, Ding L, Su LY, An WS, et al. Elevated temperature increases perivascular adipose tissue via the AMPK-eNOS pathway in diet-induced obese mice. Front Physiol. 2017;8:550–7.

43. Hou N, Liu Y, Han F, Wang D, Hou X, Hou S, et al. Irisin improves perivascular adipose tissue dysfunction via regulation of the heme oxygenase-1/adiponectin axis in diet-induced obese mice. J Mol Cell Cardiol. 2016;99:188–96.

44. Lynch FM, Withers SB, Yao Z, Werner ME, Edwards G, Weston AH, et al. Perivascular adipose tissue-derived adiponectin activates BKCa channels to induce anticontractile responses. Am J Physiol Heart Circ Physiol. 2013;304:H786–95.

45. Baylie R, Ahmed M, Bonev AD, Hill-Eubanks DC, Heppner TJ, Nelson MT, et al. Lack of direct effect of adiponectin on vascular smooth muscle cell BK Ca channels or Ca2+ signaling in the regulation of small artery pressure-induced constriction. Physiol Rep. 2017;5:1–11.

46. Han F, Zhang Y, Shao M, Mu Q, Jiao X, Hou N, et al. C1q/TNF-related protein 9 improves the anti-contractile effects of perivascular adipose tissue via the AMPK-eNOS pathway in diet-induced obese mice. Clin Exp Pharmacol Physiol. 2018;45:50–7.

47. Han F, Liu Y, Han F, Wang D, Hou X, Hou S, et al. Irisin improves perivascular adipose tissue dysfunction via regulation of the heme oxygenase-1/adiponectin axis in diet-induced obese mice. J Mol Cell Cardiol. 2016;99:188–96.

48. Xia N, Horke S, Habermeier A, Closs EI, Reifenberg G, Gerike A, et al. Uncoupling of endothelial nitric oxide synthase in perivascular adipose tissue of diet-induced obese mice. Arterioscler Thromb Vasc Biol. 2016;36:78–85.

49. Araujo HN, Valgas Da Silva CP, Sponton ACS, Clerici SP, Davel AP, Antunes E, et al. Perivascular adipose tissue and vascular responses in healthy trained rats. Life Sci. 2015;125:79–87.

50. Manka D, Chatterjee TK, Stoll LL, Basford JE, Konaniah ES, Arking DE, et al. Perivascular adipose tissue and vascular remodeling. Circ Res. 2009;105:906–11.

51. Ying R, Chen J, Yang Y, Zhang H, Chen Y, Wang J. Transplanted perivascular adipose tissue promotes destabilization of atherosclerotic plaque in apolipoprotein E-deficient mice. J Am Coll Cardiol Found. 2017;69:2034.

52. Moitra J, Mason MM, Olive M, Krylov D, Gavrilova O, Marcus-Samuels B, et al. Life without white fat: a transgenic mouse. Genes Dev. 1998;12:12168–81.

53. Takemori K, Gao YJ, Ding L, Lu C, Su LY, An WS, et al. Elevated blood pressure in transgenic lipoprotein mice and altered vascular function. Hypertension. 2007;49:365–72.

54. Blüher M. Transgenic animal models for the study of adipose tissue biology. Best Pract Res Clin Endocr Metab. 2005;19:605–23.

55. Lowell BB, Susolic SV, Hamann A, Lawitts JA, Himms-Hagen J, Boyer BB, et al. Development of obesity in transgenic mice after genetic ablation of brown adipose tissue. Nature. 1993;366:740–2.

56. Lowell B, Israel B, Hospital BL. Decreased brown fat markedly enhances susceptability to diet-induced obesity, diabetes, and hyperlipidemia. Endocrinology. 1996;137:21–9.

57. Masuzaki H, Ogawa Y, Aizawa-abe M, Hosoda K, Suga J, Wada Y, et al. Fat apoptosis through targeted activation of caspase 8: a novel mechanism for the initiation and resolution of obesity. J Biol Chem. 2005;280:18582–90.
new mouse model of inducible and reversible lipoatrophy. Nat Med. 2005;11:797–803.

57. Poulton R, Caspi A, Milne BJ, Thomson WM, Taylor A, Sears MR, et al. Vascular smooth muscle cell-selective PPARγ deletion leads to hypotension. Circulation. 2009;119:2161–9.

58. Imazumi K. Diet and atherosclerosis in apolipoprotein E-deficient mice. Biosci Biotechnol Biochem. 2011;75:1023–35.

59. Öhman MK, Luo W, Wang H, Guo C, Abdallah W, Russo HM, et al. Perivascular visceral adipose tissue induces atherosclerosis in apolipoprotein E-deficient. Atherosclerosis. 2011;219:33–9.

60. Véniant MM, Shannon Withecombe SGY. Periaortic adipose tissue—specific activation of the renin-angiotensin system contributes to atherosclerosis development in uninephrectomized apoE/- mice. Am J Physiol Heart Circ Physiol. 2013;305:H667–75.

61. Sakaue T, Suzuki J, Hamaguchi M, Suehiro C, Tanino A, Nago T, et al. Perivascular adipose tissueangiostenin II type 1 receptor promotes vascular inflammation and aneurysm formation. Hypertension. 2017;70:780–9.

62. Yang J, Villar VAM, Jones JE, Jose PA, Zeng C. Lipoprotein size and atherosclerosis susceptibility in Apoe(-/-) and Ldlr(-/-) mice. Arter Thromb Vasc Biol. 2001;21:1567–70.

63. Du B, Ouyang A, Eng JS, Fleenor BS. Aortic perivascular adipose-tissue-derived interleukin-6 contributes to arterial stiffness in low-density lipoprotein receptor deficient mice. Am J Physiol Circ Physiol. 2015;308:H1382–90.

64. Watts SW, Linder AE, Aaronson P, Davel AP, Baltieri N, Guizoni GM, et al. Protective role of perivascular adipose tissue in endothelial dysfunction and insulin-induced vasodilatation of hypercholesterolemic LDL receptor-deficient mice. Front Physiol. 2018;9:2293389.

65. Lu C, Su LY, Lee RMKW, Gao YJ. Alterations in perivascular adipose tissue structure and function in hypertension. Eur J Pharmacol. 2011;656:68–73.

66. Zavaritskaya O, Zhuravleva N, Schleifenbaum J, Gao YJ, Su LY, Devermann L, et al. Role of KCNQ channels in skeletal muscle arteries and periadventitial vascular dysfunction. Hypertension. 2013;61:151–9.

67. Tsvektov D, Tano JY, Kassmann M, Wang N, Schubert R, Gollasch M. The role of DPO-1 and XE991-sensitive potassium channels in perivascular adipose tissue-mediated regulation of vascular tone. Front Physiol. 2016;7:1–10.

68. Tsvektov D, Käßmann M, Tano J-Y, Chen L, Schleifenbaum J, Voelkl J, et al. Do Kv 7.1 channels contribute to control of arterial vascular tone? Br J Pharmacol. 2017;174:150–62.

69. Gollasch M, Welsh DG, Schubert R, Gollasch M, et al. Perivascular adipose tissue structure and function in hypertension. J Am Soc Hypertens. 2014;101:130–7.

70. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release across the arterial wall. Nature. 1987;327:524–7.

71. Lu C, Su LY, Sharma AM, RMKW L. Modulation of perivascular adipose tissue by endothelium-derived hyperpolarizing factor. Am J Physiol Heart Circ Physiol. 2004;286:H1107–13.

72. Schleifenbaum J, Köhn C, Voblova N, Dubrovská G, Zavaritskaya O, Gloe T, et al. Systemic peripheral artery relaxation by KCNQ channel openers and hydrogen sulfide. J Hypertens. 2010;28:1875–82.

73. Yang G, Wu L, Jiang B, Yang W, Qi J, Cao K, et al. H2S as a Physiologic vasorelaxant: hypertension in mice with deletion of cystathionine γ-lyase. Science. 2008;322(8):587–90.

74. Be J. Systemic peripheral artery relaxation by KCNQ channel openers and hydrogen sulfide. Can J Physiol Pharmacol. 2013;89:889–98.

75. Fang L, Zhao J, Chen Y, Ma T, Xu G, Tang C, et al. Hydrogen sulfide derived from periadventitial adipose tissue is a vasodilator. J Hypertens. 2009;27:2174–85.

76. Köhn C, Schleifenbaum J, Szijártó IA, Markó L, Dubrovská G, Huang Y, et al. Differential effects of cystathionine-γ-lyase-dependent vasodilatory H2S in periadventitial vasoregulation of rat and mouse aortas. PLoS One. 2012;7:1–9.

77. Szijártó IA, Markó L, Miljkovic MR, Tselikis E, Tselikis E, et al. Cystathionine-γ-lyase-produced hydrogen sulfide controls endothelial NO bioavailability and blood pressure. Hypertension. 2018;71:1210–7.

78. Liaochev SI, Fridovich I. The effects of superoxide dismutase on H2O2 formation. Free Radic Biol Med. 2007;42:1465–9.

79. Suvorava T, Kojda G. Reactive oxygen species as cardiovascular mediators: lessons from endothelial-specific protein overexpression mouse models. Biochim Biophys Acta - Bioenerg. 2009;1787:802–10.

80. Shimokawa H, Morikawa K. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in animals and humans. J Mol Cell Cardiol. 2005;39:725–32.

81. Moncada S, Higgs EAV. Human arterial and venous tissues generate prostacyclin (prostaglandin I2), a potent inhibitor of platelet aggregation. Lancet. 1977;1:18–21.

82. Davidge ST, Prostaglandin H synthase and vascular function. Circ Res. 2001;89:650–60.

83. Ozen G, Topal G, Gomez I, Ghoreschi A, Boukais K, Benyahia C, et al. Control of human vascular tone by prostanooids derived from perivascular adipose tissue. Prostaglandins Other Lipid Mediat. 2013;107:13–7.

84. Majed BH, Khalil RA. Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn. Pharmacol Rev. 2012;64:540–82.

85. Li PL, Zou AP, Campbell WB. Regulation of potassium channels in coronary arterial smooth muscle by endothelium-derived vasodilators. Hypertension. 1997;29:262–7.

86. Xia N, Li H. The role of perivascular adipose tissue in obesity-induced vascular dysfunction. Br J Pharmacol. 2017;174:3425–42.

87. Hill MA, Matchkov VV, Murphy T, Wang N, Gollasch M, Kuczumanski A, et al. Palmitic acid methyl ester and its relation to control of tone of human visceral arteries and rat aortas by perivascular adipose tissue. 2018;9:1–10.

88. Hass A, Oz H, Mashavi M, Shargorodsky M. Role of RAAS and adipokines in cardiovascular protection: effect of different doses of angiotensin II receptor blocker on adipokines level in hypertensive patients. J Am Soc Hypertens. 2014;8:709–14.

89. Cat AND, Briones AM, Callera GE, Yogi A, He Y, Montezano AC, et al. Adipocyte-derived factors regulate vascular smooth muscle cells through mineralocorticoid and glucocorticoid receptors. Hypertension. 2011;58:479–88.

90. Heitsch H, Brovkovych S, Malinski T, Wiemer G. Angiotensin (1–7)-stimulated nitric oxide and superoxide release from endothelial cells. Hypertension. 2001;37:72–6.

91. Gollasch M, Dubrovská G. Paracrine role for periadventitial adipose tissue in the regulation of arterial tone. Trends Pharmacol Sci. 2004;25:647–53.
gene-related peptide expression and release. Brain Res. 1995;686:77–86.

219. Marti E, Gibson SJ, Polak JM, Facer P, Springall DR, Van Aswegen G, et al. Ontogeny of peptide- and amine-containing neurones in motor, sensory, and autonomic regions of rat and human spinal cord, dorsal root ganglia, and rat skin. J Comp Neurol. 1987;266:332–59.

220. Somasundaram C, Diz DI, Coleman T, Bukoski RD. Adventitial neuronal somata. J Vasc Res. 2006;43:278–88.

221. Mohammed MMJ, Myers DS, Sofola OA, Hainsworth R, Drinkhill MJ. Vasodilator effects of leptin on canine isolated mesenteric arteries and veins. Clin Exp Pharmacol Physiol. 2007;34:771–4.

222. Nakagawa K, Higashi Y, Sasaki S, Oshima T, Matsuura H, Chayama K. Leptin causes vasodilation in humans. Hypertens Res. 2002;25:161–5.

223. Kimura K, Tsuda K, Baba A, Kawabe T, Boh-Oka SI, Ibata M, et al. Involvement of nitric oxide in endothelium-dependent arterial relaxation by leptin. Biochem Biophys Res Commun. 2000;273:745–9.

224. Lembo G, Vecchione C, Fratta L, Marino G, Tramurco V, D’Amati G, et al. Leptin induces direct vasodilation through distinct endothelial mechanisms. Diabetes. 2000;49:293–7.

225. de Lartigue G, Ronveaux CC, Raybould HE. Deletion of leptin signaling in vagal afferent neurons results in hyperphagia and obesity. Mol Metab. 2014;3:595–607.

226. Fésüs G, Dubrovska G, Gorzelniak K, Kluge R, Huang Y, Luft FC, et al. Adiponectin is a novel humoral vasodilator. Cardiovasc Res. 2007;75:719–27.

227. Löhn M, Dubrovska G, Lauterbach B, Luft FC, Gollasch M, Sharma AM. Periadventitial fat releases a vascular relaxing factor. FASEB J. 2002;16:1057–63.

228. Eguchi A, Mulya A, Lazic M, Radhakrishnan D, Berk MP, Povero D, et al. Microparticles release by adipocytes act as “find-me” signals to promote macrophage migration. PLoS One. 2015;10:1–19.